The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Besides the 0.2M drawdown in February any thoughts why another drawdown of up to 1.4M are also agreed on due in February? What shall it be for when results are expected in early or late Q2?
A fourth deposit, on the 6-month anniversary of the date of the First Deposit, of up to £1.4 million (the "Fourth Deposit") subject to the Customary Conditions (defined below) and the following trading conditions: a, b, c ..
Action is much appreciated, PCS. Even though, I guess answers, if any, will be as poor as it was re the rental lease. BOS had a. chance but failed to build some confidence simply in confirming a new short or long term rental contract, IMHO.
Totally agree Warthog. It is more than annoying how this bulletin board is being manipulated by a few. Nothing has been wrong David's post late night to question and clarify ThePuma's role among this audiance. On the contrary, post was brilliant and a honest balanced view.
It is disgusting how opposing views are being ignored and financial statements and facts are fully ignored not worth to being discussed at all.
Thanks for sharing your analysis.
"Riverfort also receives warrants equal to 40% of the drawdown at the recalculated reference price, exercisable at 140% of this reference price. "
I suggest an agreement about the warrants in connection with a presumably regulated (?) holding period of at least four month would have been favourable and in Sareum's say our PI's interest.
Given the foreseeable good data and science, not sure why such condition was impossible while expecting the good news in due course.
Sareum might have been illiquid the time BOD pulled out the RF facility not only dor the science but to safeguard their wage pay day, also.
That s my haunch. Obviously, there are no rules in place for AIM listed companies to announce a financial mess nor is there most likely no supervisory board at hand to claim an appropriate examination re the ongoings.
The BOD have been doing well and have come well so far supported by Toth2 and the like who already knew from scratch or may I say from a patent only and a sh price of approx GBP 0.00001 at the time that this science will come big. Fair enough he recommended to read "The Reminiscenses of a stock operator". Highly recommended. Had I read this book earlier, I had known to handle the sh consolidation right and sell (also) at the high's.
I have 1,500 shares left over. Not buying. Rose tinted glasses put off.
GLA
Many thks, HBD. I really was puzzled and obviously have no clue how Pharma and research does work in time and detail. I think its a good thing then when SR737 was in play all the time.
I recall a time when SAR had to drop an RNS just to confirm what this Board had already found out themselves. Not sure if it was about MERCK and their results at the time. RNS imminent?
GLA
Hi Ben
In case of a take out say Merger Sareum might keep going as a legal entity listed on AIM but belong to the new owner. Also, in case Sareum goes bust the buyer will pay the billions or lump sum and any party shall being compensated in relation and according to their holding nevertheless keep the ranking in mind. Shareholders will being compensated last after debt are being paid.
Thats my understanding.
It feels a bit awkward that CRF is willing to participate in a privately held company as they will do when participating with a contribution in kind.
Am I mistaken? I am happy to be proven wrong?
Suspicious I am meanwhile, I ackknowledge the hard work done over Christmas though to nail this deal.
A happy new Year everybody.
Anyone to correct me , please when I am wrong, actually. I extract and quote from RNS lately feom November
As announced on 2 November 2023, Dr Tim Mitchell, Chief Executive Officer, and Dr John Reader, Chief Scientific Officer, each exercised options over 95,040 ordinary shares of 1.25 pence each in the Company (the "Options Exercise"), at an exercise price of 30 pence per ordinary share.
Of those shares received pursuant to the Options Exercise, Dr Mitchell and Dr Reader have retained 23,040 and 44,614 ordinary shares, respectively, following the sale of 72,000 and 50,426 ordinary shares, respectively, at a price of 56.8 pence per ordinary share (the "Share Sales"). The Share Sales were undertaken partly in order to compensate for the cost and tax liabilities arising from the Options Exercise.